Download PDF
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2024; 07(04): 176-184
DOI: 10.1055/s-0044-1791484
Original Article

Efficacy and Safety of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use during Ramadan Fasting: A Systematic Review

Elamin Abdelgadir 
1   Mohamed Bin Rashid University, Dubai, United Arab Emirates
2   Dubai Hospital, Dubai Academic Health Corporation, Dubai, United Arab Emirates
,
Alaaeldin Bashier 
2   Dubai Hospital, Dubai Academic Health Corporation, Dubai, United Arab Emirates
,
Faryal Ashfaq
2   Dubai Hospital, Dubai Academic Health Corporation, Dubai, United Arab Emirates
,
Mohamed Hassanein 
1   Mohamed Bin Rashid University, Dubai, United Arab Emirates
2   Dubai Hospital, Dubai Academic Health Corporation, Dubai, United Arab Emirates
,
Salem A. Beshyah 
3   Department of Medicine, Dubai Medical College for Girls, Dubai, United Arab Emirates
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Religious intermittent fasting for 30 days during Ramadan may increase the risk of dehydration, hypovolemia, and hypoglycemia. These events may also be encountered when using sodium-glucose cotransporter 2 inhibitors (SGLT2is).

Objectives This article evaluates the safety of the SGLT2 inhibitors in people with type 2 diabetes during Ramadan.

Search Methods We searched PubMed CENTRAL, MEDLINE, and Google Scholar on July 25, 2023 without language restrictions.

Selection Criteria All trials assessing the safety of SGLT2 inhibitors during Ramadan were assessed and summarized into preset points.

Data Extraction Two authors independently extracted and reviewed the retrieved studies. A third author reviewed the merged summary of the two authors and modified the article when necessary.

Results Diabetic ketoacidosis, hospitalization due to diabetes-related problems, and thrombosis were either not significantly related to SGLT2i use or not studied. Estimated glomerular filtration rate (eGFR) dropped significantly in one study; otherwise, it was either not statistically significant or not studied. Hypovolemia and dehydration were significantly increased in one study only.

Conclusion From the available evidence, the use of SGLT2 inhibitors in people with diabetes during Ramadan seems to be safe and well tolerated. Hypovolemia and a drop in eGFR were reported in a few studies, with no reported clinical significance.

Keywords

fasting - Ramadan - Ramadan fasting - safety - SGLT2i

Authors' Contributions

All named authors contributed to the study's conception and conduct and to the manuscript's drafting and finalization. They have all reviewed and approved its final version.


Funding

None.


Compliance with Ethical Principles

Ethical approval is not required for a systematic review type of study.


Note

E.A., A.B., S.B., M.H. reported:


Presenting in medical platforms which may be compensated by an agreed upon honoraria.


A.B., F.Y., M.H., S.B. reported:


Payment or honoraria for lectures and support for major academic conferences.




Publication History

Article published online:
16 October 2024

© 2024. Gulf Association of Endocrinology and Diabetes (GAED). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Salti I, Bénard E, Detournay B. et al; EPIDIAR study group. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27 (10) 2306-2311
    CrossrefPubMedSearch in Google Scholar
  • 2 Abdelgadir EI, Hassanein MM, Bashier AM. et al. A prospective multi-country observational trial to compare the incidences of diabetic ketoacidosis in the month of Ramadan, the preceding month, and the following month (DKAR international). J Diabetes Metab Disord 2016; 15: 50
    CrossrefPubMedSearch in Google Scholar
  • 3 Beshyah SA, Hassanein M, Ahmedani MY. et al. Diabetic hypoglycaemia during Ramadan fasting: a trans-national observational real-world study. Diabetes Res Clin Pract 2019; 150: 315-321
    CrossrefPubMedSearch in Google Scholar
  • 4 Lee SWH, Chen WS, Sellappans R, Md Sharif SB, Metzendorf MI, Lai NM. Interventions for people with type 2 diabetes mellitus fasting during Ramadan. Cochrane Database Syst Rev 2023; 7 (07) CD013178
    PubMedSearch in Google Scholar
  • 5 Davies MJ, D'Alessio DA, Fradkin J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41 (12) 2669-2701
    CrossrefPubMedSearch in Google Scholar
  • 6 Buse JB, Wexler DJ, Tsapas A. et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43 (02) 487-493
    CrossrefPubMedSearch in Google Scholar
  • 7 Davies MJ, Aroda VR, Collins BS. et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65 (12) 1925-1966
    CrossrefPubMedSearch in Google Scholar
  • 8 Ni X, Zhang L, Feng X, Tang L. New hypoglycemic drugs: combination drugs and targets discovery. Front Pharmacol 2022; 13: 877797
    CrossrefPubMedSearch in Google Scholar
  • 9 Handelsman Y. Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Adv Ther 2019; 36 (10) 2567-2586
    CrossrefPubMedSearch in Google Scholar
  • 10 Hassanein M, Echtay A, Hassoun A. et al. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). Int J Clin Pract 2017; 71 (10) e12991
    CrossrefPubMedSearch in Google Scholar
  • 11 Wan Seman WJ, Kori N, Rajoo S. et al. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes Obes Metab 2016; 18 (06) 628-632
    CrossrefPubMedSearch in Google Scholar
  • 12 Bashier A, Khalifa AA, Abdelgadir EI. et al. Safety of sodium-glucose co-transporter 2 inhibitors (SGLT2-I) during the month of Ramadan in Muslim patients with type 2 diabetes. Oman Med J 2018; 33 (02) 104-110
    CrossrefPubMedSearch in Google Scholar
  • 13 Shao Y, Lim GJ, Chua CL. et al. The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes. Diabetes Res Clin Pract 2018; 142: 85-91
    CrossrefPubMedSearch in Google Scholar
  • 14 Abdelgadir E, Rashid F, Bashier A. et al. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes. Diabetes Metab Syndr 2019; 13 (05) 2927-2932
    CrossrefPubMedSearch in Google Scholar
  • 15 Sheikh A, Das B, Sattar S, Islam N. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population-an observational study from a tertiary care center in Karachi. Endocrine 2023; 80 (01) 64-70
    CrossrefPubMedSearch in Google Scholar
  • 16 Ahmed I, Raja UY, Wahab MU. et al. Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. BMC Endocr Disord 2022; 22 (01) 247
    CrossrefPubMedSearch in Google Scholar
  • 17 Pathan MDF, Akter N, Selim S. et al. Efficacy and safety of empagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: a real-world study from Bangladesh. Diabetes Metab Syndr Obes 2022; 15: 4011-4021
    CrossrefPubMedSearch in Google Scholar
  • 18 Goh KG, Zakaria MH, Raja Azwan RN, Bhajan Singh KK, Badrul Hisham MH, Hussein Z. Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia. Diabetes Metab Syndr 2023; 17 (01) 102680
    CrossrefPubMedSearch in Google Scholar
  • 19 Samkari MM, Bokhari NS, Alhajaji R. et al. Safety and tolerability of empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: a prospective cohort study. Saudi Pharm J 2023; 31 (06) 972-978
    CrossrefPubMedSearch in Google Scholar
  • 20 Ruqaib AMA, Ghamdi AAA, Jamaan AA. et al. Association between sglt2 inhibitors and diabetic ketoacidosis among patients fasting in Ramadan. Research Square 2023;
    CrossrefSearch in Google Scholar
  • 21 Yousuf S, Ahmedani MY. Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting. Diabetes Metab Syndr 2022; 16 (11) 102633
    CrossrefPubMedSearch in Google Scholar
  • 22 Ibrahim M, Abu Al Magd M, Annabi FA. et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care 2015; 3 (01) e000108
    CrossrefPubMedSearch in Google Scholar
  • 23 Ali S, Davies MJ, Brady EM. et al. Guidelines for managing diabetes in Ramadan. Diabet Med 2016; 33 (10) 1315-1329
    CrossrefPubMedSearch in Google Scholar
  • 24 Hassanein M, Al-Arouj M, Hamdy O. et al; International Diabetes Federation (IDF), in collaboration with the Diabetes and Ramadan (DAR) International Alliance. Diabetes and Ramadan: practical guidelines. Diabetes Res Clin Pract 2017; 126: 303-316
    CrossrefPubMedSearch in Google Scholar
  • 25 Beshyah SA, Chatterjee S, Davies MJ. Use of SGLT2 inhibitors during Ramadan: a survey of physicians' views and practical guidance. Br J Diabetes 2016; 16: 20-24
    CrossrefSearch in Google Scholar
  • 26 Beshyah SA, Farooqi MH, Suliman SG. et al. Use of sodium-glucose co-transporter 2 inhibitors during the fasting of Ramadan: is there cause for concern?. Ibnosina J Med Biomed Sci 2016; 8 (03) 81-88
    Thieme ConnectSearch in Google Scholar
  • 27 Bajaj HS, Abouhassan T, Ahsan MR. et al. Diabetes Canada position statement for people with types 1 and 2 diabetes who fast during Ramadan. Can J Diabetes 2019; 43 (01) 3-12
    CrossrefPubMedSearch in Google Scholar
  • 28 Hassanein M, Afandi B, Yakoob Ahmedani M. et al. Diabetes and Ramadan: practical guidelines 2021. Diabetes Res Clin Pract 2022; 185: 109185
    CrossrefPubMedSearch in Google Scholar
  • 29 Beshyah SA, Hafidh K, Shaikh TG. Evolving physicians' perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2020; 168: 108389
    CrossrefPubMedSearch in Google Scholar
  • 30 Hassanein M, Bashier A, Randeree H. et al. Use of SGLT2 inhibitors during Ramadan: an expert panel statement. Diabetes Res Clin Pract 2020; 169: 108465
    CrossrefPubMedSearch in Google Scholar